COPENHAGEN, Denmark ― Adding a novel anti–nerve growth factor product to opioids for terminally ill patients with inadequately controlled cancer pain did not significantly improve average cancer pain ...
HONG KONG, Feb. 10, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the clinical trial application of the innovative nerve growth factor (NGF) monoclonal antibody (research and development ...
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy (EPP) for malignant pleural mesothelioma (MPM): An Italian experience with cisplatin-based regimens No significant financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results